无症状BRCA1/2致病性变异携带者降低风险输卵管卵巢切除术时高级别浆液性癌的患病率与临床因素
本研究纳入1995至2018年荷兰遗传性乳腺癌卵巢癌研究中接受降低风险输卵管卵巢切除术的无症状BRCA1/2致病性变异携带者2557例,经病理复核发现BRCA1携带者高级别浆液性癌患病率为1.5%,BRCA2携带者为0.6%,73%原发灶位于输卵管,推荐年龄手术者患病率为0.4%,年龄较大增加风险而长期口服避孕药具保护作用。
要点
- BRCA1携带者RRSO时HGSC患病率1.5%,BRCA2携带者0.6%。
- 73%的HGSC原发部位为输卵管,支持输卵管起源假说。
- 推荐年龄行RRSO者HGSC患病率为0.4%,长期OCP使用具保护作用。
核心结论
- 在无症状BRCA1/2-PV携带者的RRSO标本中,BRCA1-PV者HGSC患病率为1.5%,BRCA2-PV者为0.6%。
- 多数病变位于输卵管,与输卵管假说一致。
- 结果强调及时行RRSO并完整切除和评估输卵管的重要性,并显示长期OCP的保护效应。
研究设计与样本
- 研究纳入1995至2018年荷兰遗传性乳腺癌卵巢癌研究中的BRCA1/2-PV携带者,共2557例,其中BRCA1-PV 1624例、BRCA2-PV 930例、同时携带BRCA1/2-PV 3例。
- 对所有病理报告进行筛查,并对有上皮异常或正常RRSO后发生HGSC的RRSO标本进行组织病理学复核。
- 比较RRSO时伴与不伴HGSC女性的临床特征,包括产次和口服避孕药使用。
主要发现
- BRCA1-PV携带者RRSO时中位年龄43.0岁(范围25.3-73.8),BRCA2-PV携带者为46.8岁(范围27.6-77.9)。
- 组织病理学复核确认29例HGSC中的28例,并从20例外观正常的RRSO标本中另发现2例HGSC。
- 24例(1.5%)BRCA1-PV携带者和6例(0.6%)BRCA2-PV携带者在RRSO时患有HGSC,73%的原发部位为输卵管。
- 在推荐年龄行RRSO的女性中HGSC患病率为0.4%。
- 在BRCA1/2-PV携带者中,RRSO时年龄较大增加HGSC风险,长期OCP使用具保护作用。
临床怎么用
- 作者结论强调及时行RRSO并完整切除和评估输卵管的重要性,并显示长期OCP的保护效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the prevalence of and clinical factors associated with high-grade serous carcinoma (HGSC) at risk-reducing salpingo-oophorectomy (RRSO) in asymptomatic BRCA1/2-pathogenic variant (PV) carriers. PATIENTS AND METHODS: We included BRCA1/2-PV carriers who underwent RRSO between 1995 and 2018 from the Hereditary Breast and Ovarian cancer in the Netherlands study. All pathology reports were screened, and histopathology reviews were performed for RRSO specimens with epithelial abnormalities or where HGSC developed after normal RRSO. We then compared clinical characteristics, including parity and oral contraceptive pill (OCP) use, for women with and without HGSC at RRSO. RESULTS: Of the 2,557 included women, 1,624 had BRCA1, 930 had BRCA2, and three had both BRCA1/2-PV. The median age at RRSO was 43.0 years (range: 25.3-73.8) for BRCA1-PV and 46.8 years (27.6-77.9) for BRCA2-PV carriers. Histopathologic review confirmed 28 of 29 HGSCs and two further HGSCs from among 20 apparently normal RRSO specimens. Thus, 24 (1.5%) BRCA1-PV and 6 (0.6%) BRCA2-PV carriers had HGSC at RRSO, with the fallopian tube identified as the primary site in 73%. The prevalence of HGSC in women who underwent RRSO at the recommended age was 0.4%. Among BRCA1/2-PV carriers, older age at RRSO increased the risk of HGSC and long-term OCP use was protective. CONCLUSION: We detected HGSC in 1.5% (BRCA1-PV) and 0.6% (BRCA2-PV) of RRSO specimens from asymptomatic BRCA1/2-PV carriers. Consistent with the fallopian tube hypothesis, we found most lesions in the fallopian tube. Our results highlight the importance of timely RRSO with total removal and assessment of the fallopian tubes and show the protective effects of long-term OCP.
引用
- Stroot IAS, Brouwer J, Bart J, et al. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors. J Clin Oncol. 2023. PMID: 36809028. doi:10.1200/JCO.22.01237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。